Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (TROPiCS-03)
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Sponsor: Gilead Sciences
Listed as NCT03964727, this observational or N/A phase trial focuses on Metastatic Solid Tumor and remains ongoing. Sponsored by Gilead Sciences, it has been updated 43 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
43 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Feb 2026 — May 2026 [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 38 earlier versions
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Jan 2021 — May 2021 [monthly]
Suspended PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Dec 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States , Anchorage, United States , Ann Arbor, United States , Aurora, United States , Barcelona, Spain , Barcelona, Spain , Barcelona, Spain , Benowa, Australia , Blacksburg, United States , Bordeaux, France and 55 more locations